Hong Kong Pharmaceuticals Stock News

China Petroleum & Chemical (SEHK:386) has brought a new specialty polyvinyl alcohol facility online at Chongqing SVW Chemical, increasing total PVA capacity and already sending initial high-end PVA shipments to Europe. See our latest analysis for China Petroleum & Chemical. The new PVA facility news comes as China Petroleum & Chemical trades at HK$4.36, with a 30 day share price return of 6.34% after a period where the 90 day share price return declined 5.42%, while the 5 year total...

Pacific Basin Shipping reported past half-year 2026 results showing sales of US$1,105.48 million and net income of US$105.05 million, both higher than the prior-year period. The jump in basic earnings per share from US$0.005 to US$0.0206 highlights a sharp improvement in profitability from continuing operations. We’ll now examine how this strong earnings rebound, particularly the surge in net income, may influence Pacific Basin Shipping’s investment narrative. The future of work is here...

How Swire Properties’ latest earnings may shape investor thinking Swire Properties (SEHK:1972) just reported half year 2026 results that shifted from a net loss to net income of HK$3,631 million, putting the stock back in focus for many investors. See our latest analysis for Swire Properties. The earnings swing back to profit has arrived alongside a 10.3% 1 month share price return and a 10.5% year to date share price return, while a 16.7% 1 year total shareholder return and 52.7% 3 year...

Lenovo Group (SEHK:992) is back in focus after two new partnerships linked its hardware to growing AI and gaming demand, covering sovereign AI infrastructure in Saudi Arabia as well as the Esports World Cup 2026 in Paris. See our latest analysis for Lenovo Group. The latest AI and esports partnerships arrive as Lenovo Group’s share price has surged, with a 90 day share price return of 124.08% and a year to date share price return of 194.24%, while the 5 year total shareholder return sits at...

CLP Holdings earnings spark fresh look at the stock CLP Holdings (SEHK:2) has drawn investor attention after reporting half year 2026 earnings, with sales at HK$42,856 million and net income of HK$6,104 million on slightly higher earnings per share. See our latest analysis for CLP Holdings. Following the results, CLP Holdings is trading at HK$77.6, with an 11.02% year to date share price return and a 21.42% 1 year total shareholder return, suggesting momentum has been building over time. If...

Insiders who purchased CN¥40.9m worth of Future Machine Limited ( HKG:1401 ) shares over the past year recouped some of...

The recent price decline of 18% in Feiyang International Holdings Group Limited's ( HKG:1901 ) stock may have...

With the business potentially at an important milestone, we thought we'd take a closer look at Everest Medicines...

Bar Pacific Group Holdings Limited's ( HKG:8432 ) strong earnings report was rewarded with a positive stock price move...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Investors were disappointed with Success Dragon International Holdings Limited's ( HKG:1182 ) earnings, despite the...

The recent 14% drop in Qing Hua Holding Group Company Limited's ( HKG:8082 ) stock could come as a blow to insiders who...

From what we can see, insiders were net buyers in Tomson Group Limited's ( HKG:258 ) during the past 12 months. That...

Hang Lung Properties Limited ( HKG:101 ) stock is about to trade ex-dividend in 4 days. The ex-dividend date is two...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Uni-President China Holdings (SEHK:220) is in focus after reporting half-year 2026 earnings, with sales of CN¥17,321 million and net income of CN¥1,402 million, along with higher basic earnings per share from continuing operations. See our latest analysis for Uni-President China Holdings. The HK$7.70 share price has moved up in the short term, with a 1 day share price return of 3.08% and a 30 day share price return of 3.22%, although the 1 year total shareholder return is down 14.59% while...

Global inflation updates, regional GDP releases and fresh signals from central banks are about to test sentiment toward Asia’s consumer driven stocks. When money shifts on the back of data like US July CPI and China credit figures, some companies tied to everyday spending can move quickly. This article walks through three Asia Consumer Discretionary Stocks from the screener that appear most exposed to these catalysts, and why that matters for your portfolio watchlist. The stocks highlighted...

Wharf Real Estate Investment entered this earnings day with the stock up strongly over the past month, yet still carrying a reputation for losses and a stretched valuation. The headline today is simple. The company is still loss making, but the earnings hit is now much smaller than in recent halves. Net income for the first half of 2026 shows a loss of HK$176 million on revenue of HK$6,340 million. The market now has to decide whether this softer loss justifies a price that already embeds a...

In a week marked by mixed performances across major U.S. stock indexes and ongoing volatility in AI-related shares, global markets have been navigating the complexities of economic indicators and central bank decisions. As investors seek opportunities amid these fluctuations, identifying undervalued stocks becomes crucial, especially those that may offer potential value despite current market uncertainties.

InnoCare Pharma (SEHK:9969) is back in focus after China’s NMPA granted Breakthrough Therapy Designation to its orelabrutinib and mesutoclax combination for previously treated marginal zone lymphoma, following strong clinical data shared at ASCO 2026. See our latest analysis for InnoCare Pharma. The Breakthrough Therapy Designation sits against a share price of HK$13.8, with a year to date share price return of 10.4% and a three year total shareholder return of 97.14%, even though the one...

Asian markets have recently experienced fluctuations, influenced by global economic factors such as AI-related stock volatility and central bank policy decisions. For investors looking beyond established giants, penny stocks—often representing smaller or newer companies—can still present intriguing opportunities. Though the term "penny stocks" may seem outdated, these investments can offer a blend of affordability and potential growth when supported by strong financial health.

We wouldn't blame China New Energy Limited ( HKG:1156 ) shareholders if they were a little worried about the fact that...